Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin

Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms
Definitive Phase 1 QT clinical trial showed no cardiac abnormalities
SAN DIEGO, March 21, 2018 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today is providing additional details from the positive safety and efficacy findings in the Phase 2 STRIVE trial relating to the principal investigators’ efficacy assessments of programmatic indeterminate patients from the global, randomized Phase 2 STRIVE clinical trial of rezafungin. In addition, the results of its recently comple…


Leave a Reply

Your email address will not be published.